Research programme: cancer therapeutics- Treos Bio

Drug Profile

Research programme: cancer therapeutics- Treos Bio

Alternative Names: PolyPEPI™ Immunotherapy Cancer Vaccine

Latest Information Update: 10 Apr 2017

Price : $50

At a glance

  • Originator Treos Bio
  • Class Antineoplastics; Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Breast cancer; Colorectal cancer; Glioblastoma; Leukaemia; Lung cancer; Malignant melanoma; Ovarian cancer

Most Recent Events

  • 03 Apr 2017 Treos Bio files for patent protection with European Patent Office for cancer therapeutics
  • 21 Mar 2017 Preclinical trials in Breast cancer in United Kingdom (Parenteral) before March 2017
  • 21 Mar 2017 Preclinical trials in Colorectal cancer in United Kingdom (Parenteral) before March 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top